🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 16 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/10/2014 | 99,25 | 103,19 | 97,77 | 101,26 | +0,16% | 5,46% | 1.822.700 |
| 15/10/2014 | 102,00 | 103,75 | 96,43 | 101,10 | -3,03% | 7,18% | 2.353.900 |
| 14/10/2014 | 107,02 | 107,79 | 103,30 | 104,26 | -1,56% | 4,20% | 1.801.700 |
| 13/10/2014 | 106,74 | 109,94 | 105,63 | 105,91 | +1,13% | 4,04% | 2.409.300 |
| 10/10/2014 | 105,26 | 108,41 | 104,11 | 104,73 | -0,51% | 4,09% | 2.012.000 |
| 09/10/2014 | 105,79 | 109,15 | 103,78 | 105,27 | -1,64% | 5,08% | 1.578.300 |
| 08/10/2014 | 103,48 | 107,67 | 102,53 | 107,02 | +4,07% | 4,97% | 1.467.000 |
| 07/10/2014 | 104,70 | 106,04 | 102,72 | 102,83 | -2,77% | 3,17% | 1.237.100 |
| 06/10/2014 | 109,37 | 110,55 | 104,40 | 105,76 | -2,61% | 5,62% | 1.462.500 |
| 03/10/2014 | 105,37 | 109,08 | 103,79 | 108,59 | +3,62% | 5,02% | 1.954.100 |
| 02/10/2014 | 107,14 | 107,37 | 101,52 | 104,80 | -2,28% | 5,46% | 2.361.700 |
| 01/10/2014 | 112,88 | 112,89 | 105,27 | 107,25 | -4,51% | 6,75% | 2.743.600 |
| 30/09/2014 | 113,37 | 114,43 | 110,58 | 112,31 | -1,40% | 3,40% | 2.439.600 |
| 29/09/2014 | 112,99 | 116,88 | 110,91 | 113,90 | +0,26% | 5,28% | 2.066.800 |
| 26/09/2014 | 112,36 | 114,24 | 110,92 | 113,60 | +3,01% | 2,95% | 2.232.300 |
| 25/09/2014 | 111,43 | 112,71 | 109,97 | 110,28 | -1,52% | 2,46% | 2.646.600 |
| 24/09/2014 | 104,84 | 112,10 | 104,10 | 111,98 | +6,81% | 7,63% | 3.776.000 |
| 23/09/2014 | 104,28 | 105,72 | 102,78 | 104,84 | +0,12% | 2,82% | 2.410.200 |
| 22/09/2014 | 103,79 | 105,37 | 102,71 | 104,71 | +0,93% | 2,56% | 2.695.700 |
| 19/09/2014 | 98,12 | 105,53 | 97,54 | 103,75 | +6,57% | 8,14% | 6.299.300 |
| 18/09/2014 | 95,00 | 97,42 | 94,32 | 97,35 | +3,02% | 3,26% | 1.413.900 |
| 17/09/2014 | 94,30 | 94,92 | 92,04 | 94,50 | +0,68% | 3,05% | 1.275.200 |
| 16/09/2014 | 92,22 | 94,30 | 91,04 | 93,86 | +1,88% | 3,54% | 1.549.600 |
| 15/09/2014 | 92,81 | 92,81 | 91,27 | 92,13 | -0,92% | 1,66% | 1.150.800 |
| 12/09/2014 | 93,97 | 93,98 | 92,05 | 92,99 | -1,34% | 2,05% | 1.215.500 |
| 11/09/2014 | 94,30 | 96,20 | 92,27 | 94,25 | -0,52% | 4,17% | 1.339.400 |
| 10/09/2014 | 93,17 | 94,98 | 92,80 | 94,74 | +1,74% | 2,34% | 1.705.200 |
| 09/09/2014 | 94,17 | 94,48 | 92,48 | 93,12 | -1,45% | 2,12% | 967.000 |
| 08/09/2014 | 95,07 | 96,40 | 94,02 | 94,49 | -0,58% | 2,50% | 1.353.100 |
| 05/09/2014 | 94,68 | 96,31 | 93,55 | 95,04 | +3,81% | 2,92% | 2.065.600 |